March of Dimes Foundation, United States; Department of Pediatrics, David Geffen School of Medicine at UCLA, United States.
Mol Genet Metab. 2017 Sep;122(1-2):1-3. doi: 10.1016/j.ymgme.2017.05.018. Epub 2017 May 30.
This commentary will focus on how we can use our knowledge about the complexity of human disease and its pathogenesis to identify novel approaches to therapy. We know that even for single gene Mendelian disorders, patients with identical mutations often have different presentations and outcomes. This lack of genotype-phenotype correlation led us and others to examine the roles of modifier genes in the context of biological networks. These investigations have utilized vertebrate and invertebrate model organisms. Since one of the goals of research on modifier genes and networks is to identify novel therapeutic targets, the challenges to patient access and compliance because of the high costs of medications for rare genetic diseases must be recognized. A recent article explored protective modifiers, including plastin 3 (PLS3) and coronin 1C (CORO1C), in spinal muscular atrophy (SMA). SMA is an autosomal recessive deficit of survival motor neuron protein (SMN) caused by mutations in SMN1. However, the severity of SMA is determined primarily by the number of SMN2 copies, and this results in significant phenotypic variability. PLS3 was upregulated in siblings who were asymptomatic compared with those who had SMA2 or SMA3, but identical homozygous SMN1 deletions and equal numbers of SMN2 copies. CORO1C was identified by interrogation of the PLS3 interactome. Overexpression of these proteins rescued endocytosis in SMA models. In addition, antisense RNA for upregulation of SMN2 protein expression is being developed as another way of modifying the SMA phenotype. These investigations suggest the practical application of protective modifiers to rescue SMA phenotypes. Other examples of the potential therapeutic value of novel protective modifiers will be discussed, including in Duchenne muscular dystrophy and glycerol kinase deficiency. This work shows that while we live in an exciting era of genomic sequencing, a functional understanding of biology, the impact of its disruption, and possibilities for its repair have never been more important as we search for new therapies.
这篇评论将集中讨论我们如何利用人类疾病的复杂性及其发病机制的知识来确定新的治疗方法。我们知道,即使是对于单一基因突变的孟德尔疾病,具有相同突变的患者也常常表现出不同的特征和结果。这种基因型与表型缺乏相关性,促使我们和其他研究人员在生物网络的背景下研究修饰基因的作用。这些研究利用了脊椎动物和无脊椎动物模式生物。由于修饰基因和网络研究的目标之一是确定新的治疗靶点,因此必须认识到由于治疗罕见遗传性疾病的药物费用高昂,患者获得和遵守治疗的挑战。最近的一篇文章探讨了保护修饰基因,包括 plastin 3(PLS3)和 coronin 1C(CORO1C)在脊髓性肌萎缩症(SMA)中的作用。SMA 是由于 SMN1 突变导致生存运动神经元蛋白(SMN)缺失的常染色体隐性疾病。然而,SMA 的严重程度主要取决于 SMN2 拷贝数,这导致了显著的表型变异性。与患有 SMA2 或 SMA3 的患者相比,无症状的 SMA 患者的 PLS3 表达上调,但具有相同的纯合 SMN1 缺失和相同数量的 SMN2 拷贝。CORO1C 是通过对 PLS3 相互作用组的研究确定的。这些蛋白的过表达可挽救 SMA 模型中的内吞作用。此外,正在开发反义 RNA 来上调 SMN2 蛋白的表达,作为修饰 SMA 表型的另一种方法。这些研究表明,保护修饰基因在拯救 SMA 表型方面具有实际应用价值。还将讨论其他新型保护修饰基因的潜在治疗价值的例子,包括在杜氏肌营养不良症和甘油激酶缺乏症中的应用。这项工作表明,虽然我们生活在基因组测序的激动人心的时代,但随着我们寻找新的治疗方法,对生物学的功能理解、其破坏的影响以及修复的可能性从未像现在这样重要。